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The outcome of treatment with antidepressants varies markedly across people with the same diagnosis.
A clinically signiﬁcant prediction of outcomes could spare the frustration of trial and error approach and
improve the outcomes of major depressive disorder through individualized treatment selection. It is
likely that a combination of multiple predictors is needed to achieve such prediction. We used elastic net
regularized regression to optimize prediction of symptom improvement and remission during treatment
with escitalopram or nortriptyline and to identify contributing predictors from a range of demographic
and clinical variables in 793 adults with major depressive disorder. A combination of demographic and
clinical variables, with strong contributions from symptoms of depressed mood, reduced interest,
decreased activity, indecisiveness, pessimism and anxiety signiﬁcantly predicted treatment outcomes,
explaining 5e10% of variance in symptom improvement with escitalopram. Similar combinations of
variables predicted remission with area under the curve 0.72, explaining approximately 15% of variance
(pseudo R2) in who achieves remission, with strong contributions from body mass index, appetite,
interest-activity symptom dimension and anxious-somatizing depression subtype. Escitalopram-speciﬁc
outcome prediction was more accurate than generic outcome prediction, and reached effect sizes that
were near or above a previously established benchmark for clinical signiﬁcance. Outcome prediction on
the nortriptyline arm did not signiﬁcantly differ from chance. These results suggest that easily obtained
demographic and clinical variables can predict therapeutic response to escitalopram with clinically
meaningful accuracy, suggesting a potential for individualized prescription of this antidepressant drug.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).).
Ltd. This is an open access article u1. Introduction
Major depressive disorder is a common condition, responsible
for a substantial proportion of disability world-wide (Whiteford
et al., 2013). Although a number of pharmacological andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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unsatisfactory. While some individuals experience dramatic im-
provements, most do not beneﬁt sufﬁciently from the ﬁrst treat-
ment and have to undergo multiple treatment trials. Each trial
takes weeks, with delays causing frustration, prolonging disability
and risking adverse outcomes, including suicide. The unsatisfactory
state of depression therapeutics has led to the consensus that
diagnosis of depression may not be sufﬁcient for treatment selec-
tion and additional information needs to be considered to estimate
which treatment is likely to work for whom (Kupfer et al., 2012).
There is little evidence to guide clinicians in selecting a treat-
ment for a given individual (Simon and Perlis, 2010). A single piece
of information is unlikely to predict treatment outcome with an
accuracy that is meaningful in clinical practice. Therefore, multiple
factors may have to be considered to make the best prediction of
outcomes at the individual level. The need for prediction at indi-
vidual level has prompted the use of new methods, such as ma-
chine learning and statistical learning (Hastie et al., 2009). Unlike
traditional statistics that focus on testing whether a single variable
makes a statistically signiﬁcant contribution, learning methods
consider all available information across a number of variables to
make the best prediction for an individual. The accuracy of pre-
diction can then be compared to a standard benchmark to evaluate
whether it is likely to be clinically signiﬁcant (Uher et al., 2012d), i.e.
whether it makes a meaningful difference to a particular individual.
Individualized treatment selection could be useful if it is based
on predictors that are easily obtained (e.g. questionnaires and rat-
ing scales) and if it can differentially predict outcomes with alter-
native treatments. Two prior studies suggest that meaningful
prediction of treatment outcomes from easy-to-obtain variables is
achievable. A study of the STAR*D cohort found that 48 de-
mographic and clinical variables robustly predicted treatment
success with a clinically signiﬁcant effect size (area under the curve
0.71, 11.4% variance explained) (Perlis, 2013). The prediction was
robust in stringent validation test. A second study found that the
relative beneﬁts of cognitive-behavioural therapy and antidepres-
sant medication can be predicted from eight demographic and
clinical variables in a way that makes a meaningful difference in
outcomes for 60% of 154 participants (DeRubeis et al., 2014). While
both studies show promising results, they also leave caveats. The
STAR*D study predicted overall outcome rather than outcomes of
speciﬁc treatments. The strongest predictor was race, raising
questions about how the ﬁndings generalize to populations with
different ethnic composition. The study of cognitive-behavioural
therapy and antidepressants established differential prediction,
but due to a limited sample size, it had to derive a small number of
predictors based on results obtained in the same sample and relied
on a less stringent leave-one-out cross-validation.
Therefore, in the present study we evaluate to what extend can
demographic and clinical variables predict outcomes with speciﬁc
treatments at the level of individual. We have applied statistical
learning to a study comparing treatment with two different anti-
depressants in an ethnically homogeneous sample large enough to
allow robust 10-fold-split-sample cross-validation and permuta-
tions (Kohavi, 1995; Perez-Guaita et al., 2015).
2. Materials and methods
2.1. Study design and sample
The Genome-based Therapeutic Drugs for Depression (GENDEP)
is a 12-week comparative study that aims to personalize treatment
choice in major depressive disorder using clinical and genetic
predictors of response to a serotonin-reuptake-inhibiting antide-
pressant escitalopram and a norepinephrine-reuptake-inhibitingantidepressant nortriptyline (Uher et al., 2009a, 2010). GENDEP
included 868 treatment-seeking adults of White-European
ethnicity from nine centers, diagnosed with ICD-10/DSM-IV major
depressive disorder and a current depressive episode of at least
moderate severity established with the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN) interview (Wing et al.,
1990). Exclusion criteria were personal or family history of bipo-
lar disorder or schizophrenia and active substance dependence.
Eligible patients with no contraindications were randomly allo-
cated to receive treatment with one of the two antidepressants for
12 weeks. Escitalopram is a selective serotonin reuptake inhibitor
(SSRI) and has no effect on norepinephrine reuptake. Nortriptyline
is a second-generation tricyclic antidepressant (TCA) with a much
higher afﬁnity for the norepinephrine transporter than for the se-
rotonin transporter. A protocol guided treatment with escitalopram
10e30 mg daily and nortriptyline 50e150 mg daily, adjusted ac-
cording to therapeutic effect and tolerability (Uher et al., 2009a).
Participants with contraindications or history of intolerance of one
of the drugs were offered treatment with the other drug non-
randomly (Uher et al., 2009a). Seventy-six percent of GENDEP
participants remained on the allocated antidepressant for 8 weeks
or longer. In the present study, we include 793 participants (328 on
nortriptyline and 465 on escitalopram), who had four or more
depression severity measurements, a minimumneeded to establish
at least an initial trend in clinical response. Since participants non-
randomly allocated to escitalopram and nortriptyline differed on
some clinical characteristics (Uher et al., 2009a), we also repeated
analyses restricting the sample to randomly allocated participants
(n ¼ 450) to provide drug-speciﬁc estimates in comparable sam-
ples. The ethics boards of all centers approved the protocol and all
participants signed an informed consent.2.2. Outcomes
The clinician-rated MontgomeryeÅsberg Depression Rating
Scale (MADRS) (Montgomery and Asberg, 1979), the 17-item
Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1967)
and the self-report Beck Depression Inventory (BDI) (Beck et al.,
1961) were administered at baseline and then weekly for 12
weeks with high inter-rater reliability (Uher et al., 2008, 2012c).
Following a consensus reached in a meta-analysis (Investigators
et al., 2013), we considered one primary continuous outcome and
one primary categorical outcome. The primary continuous outcome
was the percentage of improvement in MADRS score (the primary
GENDEP outcome measure) over the twelve weeks, based on week
twelve measurement if available and on the mixed effects model
best unbiased linear estimate from earlier measurements if the
week twelve measurement was missing, adjusted for center of
recruitment, age and sex (Uher et al., 2010). On average, GENDEP
participants improved by 56.2%, from a mean initial MADRS score
of 29.0 to a mean end-of-treatment MADRS score of 12.7 (Uher
et al., 2009a). The primary categorical outcome was remission,
deﬁned as a HRSD score of 7 or less on the last available mea-
surement without imputation (we have selected the HRSD since
this is the most established deﬁnition of remission; there is less
agreement about which cut-off on the MADRS should be used as a
threshold for deﬁning remission). Secondary continuous and cat-
egorical outcomes included completion of an adequate treatment
trial (six weeks or more on allocated antidepressant) and treatment
resistant depression (TRD; lack of response to two adequate anti-
depressant treatment trials, including the GENDEP treatment and
previous treatment trials). Of the analyzed sample, 326 (41.1%)
participants achieved remission on HRSD-17, 710 (89.5%)
completed an adequate treatment trial and 105 (13.3%) had TRD.
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We combined multiple predictors that were previously tested
one at a time (Supplementary Table S1) (Keers et al., 2010; Uher
et al., 2009b, 2011, 2012b, 2009a, 2012c). Demographics data
included current age, age at onset of depression, sex, smoking
status, body mass index (BMI), occupation, marital status, years of
education and number of children (Uher et al., 2009b). We included
items and total scores on baseline severity measures (MADRS,
HRSD, BDI) (Uher et al., 2012c), individual depressive symptoms
from SCAN and depression subtypes (atypical, melancholic,
anxious) (Uher et al., 2011). We included observed mood, cognitive
and neurovegetative symptom factors and six dimensions (mood,
anxiety, pessimism, interest-activity, sleep, appetite) from a pub-
lished factor analysis (Uher et al., 2008; 2012b). We further
included stressful life events (SLEs) experienced during the six
months prior to the baseline assessment (Keers et al., 2010),
measured with the List of Threatening Experiences Questionnaire
(LTE-Q) (Brugha et al., 1985). Medication history included the use of
antidepressant at the time of recruitment, any prior antidepressant
treatment, number and types of antidepressants tried (SSRI, tricy-
clic, dual, monoamine oxidase inhibitor, other) established with
Medication History Form (MHF) (Uher et al., 2012a). Four combi-
nations of variables were tested:
Combination I: Demographic data and baseline severity (60
predictors).
Combination II: Combination I plus depression subtypes,
symptoms, and dimensions (107 predictors).
Combination III: Combination II plus stressful life events (121
predictors).
Combination IV: Combination II plus medication history (125
predictors).
The combinations allowed us comparing the addition of pre-
dictors to aminimal set of variables just including demographic and
baseline severity, as well as quantifying the improvement in pre-
diction when adding stressful life events and medication history to
a set of known strong predictors such as depression symptoms and
dimensions (Uher et al., 2008; 2012b). Baseline characteristics of
the whole sample and the drug subgroups are shown in
Supplementary Tables S2 and S3.
2.4. Statistical learning
Machine and statistical learning methods are designed to pro-
vide the best estimate of an outcome in a given individual from
multiple predictors. These methods use a ‘learning’ dataset to learn
from relationships between predictors and outcomes to derive the
best model for predicting an outcome. The prediction model is then
tested in a separate group of individuals, ‘testing’ dataset, to
establish how well it predicts an unknown outcome in an inde-
pendent sample. Machine learning methods are power tools for
prediction at individual level (Hastie et al., 2009), but have been
criticized as a “black box” that leaves the mechanism of the pre-
diction unexplained (Wall et al., 2003). Statistical learning is a set of
tools that integrates machine learning with additional statistical
methods for understanding complex data sets. We use the statis-
tical learning method of elastic net regularized regression (ENRR)
(Zou and Hastie, 2005) to predict continuous and categorical out-
comes and map the contribution of predictors. Regularized
regressionmodels are general linear models with penalties to avoid
extreme parameters that could cause overﬁtting. The elastic net is
an application of regularized regression that provides an efﬁcient
internal method of search and selection of predictors from a largeset of variables. Elastic net allows to estimate the combined pre-
dictive ability of a high number of variables whilst preventing the
models from overﬁtting. Final model coefﬁcients are interpreted as
in a usual regression output and allow ranking of predictors by the
magnitude of their contribution to predicting the outcome. We
used CARET (Kuhn, 2008) and GLMNET (Friedman et al., 2010) R
packages to implement a series of linear and logistic ENRR and
select predictors leading to optimized ﬁnal model for each
outcome. Following recommendations for optimized balance be-
tween variance explained and minimum bias, we tested the model
for each combination across a range of model parameters in 10-fold
cross-validation with resampling (Kohavi, 1995). In each step, we
split data randomly into 10 subsets, use 9 subsets as the training
dataset and the remaining subset as the testing dataset, so that we
use each part of the dataset once for testing. To minimize variation
across testing datasets, we repeated the 10-fold cross-validation
100 times with independent random dataset partitions, a proce-
dure that optimizes the stability of results (Kim, 2009). We tested
drug-speciﬁcity by comparing same-drug prediction (training and
testing datasets treated with the same drug) with a cross-drug
analysis (training and testing datasets treated with a different
drug). For continuous outcomes, we indexed the accuracy of pre-
diction with the coefﬁcient of determination R2, which quantiﬁes
the proportion of variance in outcome explained by the predictive
model, averaged across the 100 repeats of 10-fold-cross-validation.
Based on a consensus for clinical signiﬁcance, a benchmark was
established that a prediction with an R2 of 6.3 or greater is likely to
make a meaningful difference in clinical setting (Uher et al., 2012d).
For categorical outcomes, we indexed the accuracy of prediction as
area under the receiver operating curve (AUC), which provides a
summary measure for sensibility and speciﬁcity, averaged across
the 100 repeats of 10-fold-cross-validation. To quantify categorical
outcome prediction on a scale comparable with continuous out-
comes, we also derived a log-likelihood pseudo R2, which is robust
to differences in base rate.
2.5. Cross-validation of the models
We used permutation testing to establish the statistical signiﬁ-
cance of the predictions (Perez-Guaita et al., 2015). A distribution of
10-fold-cross-validation R2 values was computed in 1000 samples
with the outcomes randomly permuted. Then the distribution was
considered as a null distribution for the R2, and used to derive the p
values for the R2 estimators obtained using real outcome. As the
analysis was computationally intensive, we focused the calculation
on the models that best predicted the primary outcomes in our
sample. The use of compute engine from Google cloud platform, a
high performance cloud computing resource, allowed us to com-
plete such a high computing demand process.
3. Results
3.1. Predicting reduction in depressive symptoms
A model including 29 of the 60 predictors from combination I
explained a 3.85% of the variance in MADRS scores change across
treatment arms. The most relevant variables in the predictionwere
the baseline MADRS items apparent sadness and inability to feel,
HRSD item psychic anxiety, and BDI items pessimism and indeci-
siveness (Table 1).
The accuracy of prediction was higher in the drug-speciﬁc an-
alyses. In the escitalopram-treated group, 24 out of 121 variables in
combination III explained 6.32% of variance in MADRS outcome,
with BDI item indecisiveness, SCAN hopelessness and preoccupa-
tion with death, HRSD items work and interests and depressed
Table 1
Predicting reduction in depressive symptoms.
All Both antidepressants Escitalopram Nortriptyline
Sample size n ¼ 793 n ¼ 465 n ¼ 328
R2 R2 R2
Combination I 0.038 0.055 0.045
Combination II 0.034 0.059 0.041
Combination III 0.035 0.064 0.046
Combination IV 0.026 0.061 0.053
Best model: I III IV
Cross-drug prediction R2 R2
Escitalopram e 0.004
Nortriptyline 0.001 e
No. predictors retained: 29 24 122
Strongest effect size: Predictor beta Predictor beta Predictor beta
1. Apparent Sadness (MADRS) 2.14 Indecisiveness (BDI) 2.67 Apparent Sadness (MADRS) 5.49
2. Inability to feel (MADRS) 1.79 Hopelessness (SCAN) 2.19 Fatiguability (SCAN) 5.01
3. Anxiety, psychic (HRSD) 1.62 Work and interests (HRSD) 2.03 Inefﬁcient thinking (SCAN) 4.50
4. Pessimism (BDI) 1.57 Preoccupation with death (SCAN) 1.91 Depressed mood (HRSD) 4.18
5. Indecisiveness (BDI) 1.57 Depressed mood (HRSD) 1.79 Anhedonia (SCAN) 4.12
6. Work and interests (HRSD) 1.49 Problems with close people (LTE-Q) 1.68 Loss of interest (SCAN) 3.92
7. Insomnia: initial (HRSD) 1.32 Fatiguability (SCAN) 1.57 Dual-action antidepressants (MHF) 3.73
8. Psychomotor retardation (HRSD) 1.28 Phobia (SCAN) 1.39 SSRI antidepressants (MHF) 3.68
9. Worthlessness (BDI) 1.03 Early waking (SCAN) 1.30 Neurovegetative (Factor) 3.54
10. Hypochondriasis (HRSD) 1.00 Anxiety, psychic (HRSD) 1.08 Melancholic depression (SCAN) 3.27
Highest accuracy (R2) across models trained in every sample is marked in bold.
R2 ¼ coefﬁcient of determination (proportion of variance explained); beta ¼ standardized regression coefﬁcient (¼ a measure of effect size).
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strongly to the prediction (Table 1). This prediction was largely
escitalopram-speciﬁc; cross-drug prediction by models derived
from the escitalopram-treated training dataset explained only
0.14% of outcome variance in the nortriptyline-treated group. In the
nortriptyline-treated group, a model including all variables in
combination IV explained 5.32% of variance in outcome, with
strongest contributions from MADRS item apparent sadness, SCAN
fatigability, inefﬁcient thinking, and anhedonia and HRSD
depressed mood (Table 1). This model explained only 0.42% of
outcome variance in the escitalopram-treated group.
Whenwe restricted the analysis to randomly allocated patients,
48 predictors explained up to 5.13% (p value 0.03) of variance in
MADRS change overall, 14 predictors explained 10.25% (p value
0.016) among escitalopram-treated participants and 29 predictors
explained 6.49% (p value 0.235) among nortriptyline-treated par-
ticipants. (Table 2, Figs. 1 and 2). Predictions remained largely drug
speciﬁc, with cross-drug predictions explaining only 1.95% and
1.04% of outcome variance (Fig. 1).3.2. Predicting remission
Variables selected from combinations II, III and IV predicted
HRSD remission with an AUC of 0.72 and a pseudo R2 around 0.16
across treatment arms. Among the 41 selected variables from
combination IV, symptom dimensions appetite and interest-
activity, SCAN item phobia, BMI and age contributed most
strongly to predicting remission with an AUC 0.72, sensitivity 0.66,
speciﬁcity 0.66 and a.
Pseudo R2 of 0.15 in the entire sample (Table 3).
Among escitalopram-treated participants, 46 variables from
Combination IV predicted remission with an AUC 0.72, sensitivity
0.65, speciﬁcity 0.69 and pseudo R2 0.18, with symptom dimension
of appetite and interest-activity, use of benzodiazepines, SCAN
items fatigability, anhedonia, phobia, guilt and loss of interest, age
and smoking status contributing the most. In cross-drug analyses,
this model predicted remission in nortriptyline-treated partici-
pants with an AUC of only 0.53 and pseudo R2 0.013. Amongnortriptyline-treated participants, 52 variables from combination II
predicted remission with an AUC 0.70, sensitivity 0.64, speciﬁcity
0.61 and a pseudo R2 0.15, with strongest contributions from
baseline BMI, symptom dimensions pessimism, loss of interest-
activity and appetite, depression subtypes anxious-somatizing
depression and melancholic, SCAN items phobia and loss of libido
and age (Table 3). This predictionwas almost entirely drug-speciﬁc,
with cross-drug analyses showing prediction at chance level (AUC
0.50; pseudo R2 0.022).
When we restricted the analysis to randomly allocated partici-
pants, the prediction further improved with highest AUC values
0.74, 0.75 and 0.72 and pseudo R2 0.22 (p value < 0.001), 0.46 (p
value < 0.001) and 0.20 (p value 0.296) for predicting remission in
the entire sample, escitalopram-treated and nortriptyline-treated
participants respectively (Table 4, Fig. 2). In all cases, the predic-
tion from a combination of variables was several-fold more accu-
rate than prediction from baseline severity alone (Fig. 1). Cross-
drug analyses showed high drug-speciﬁcity (nortriptyline-to-esci-
talopram AUC of 0.5; pseudo R2 ¼ 0.029; escitalopram-to-
nortriptyline AUC of 0.5 and a pseudo R2 ¼ 0.006) (Fig. 1).
3.3. Predicting completion of the trial
The highest AUC for predicting adequate completion of an an-
tidepressant treatment trial in the whole sample was 0.63. The
SCAN items preoccupation of death and retardation, BDI item
feeling punished, and MADRS item inability to feel contributed the
most. AUC were similar in drug-speciﬁc analyses and slightly
higher in analyses of randomly allocated participants
(Supplementary Tables S4 and S5).
3.4. Predicting treatment resistant depression
Features selected from combination II predicted TRD with an
AUC 0.67 and strongest contributions from BDI item indecisiveness,
SCAN guilty ideas of reference and depressed mood, symptom
dimension appetite and HRSD-17 late insomnia. The accuracy of
prediction was similar in drug-speciﬁc analyses. Prediction
Table 2
Predicting reduction in depressive symptoms among randomly allocated participants.
Randomly allocated Both antidepressants Escitalopram Nortriptyline
Sample size n ¼ 450 n ¼ 232 n ¼ 218
R2 R2 R2
Combination I 0.042 0.097 0.065
Combination II 0.051 0.082 0.060
Combination III 0.046 0.078 0.057
Combination IV 0.046 0.102 0.058
Best model: II IV I
Cross-drug prediction R2 R2
Escitalopram e 0.019
Nortriptyline 0.010 e
No. predictors retained: 48 14 29
Strongest effect size: Predictor beta Predictor beta Predictor beta
1. Hopelessness (SCAN) 3.13 Indecisiveness (BDI) 4.56 Psychomotor retardation (HRSD) 4.39
2. Anxiety, psychic (HRSD) 3.10 Tricyclic antidepressants (MHF) 3.42 BMI 3.82
3. Psychomotor retardation (HRSD) 2.82 Phobia (SCAN) 2.62 Low self-esteem, guilt (HRSD) 3.45
4. Suicidal thoughts (MADRS) 2.65 Somatic symptoms, general (HRSD) 2.35 Feeling punished (BDI) 3.35
5. Anxious-somatizing depr. (SCAN) 2.65 Work and interests (HRSD) 2.01 Depressed mood (HRSD) 3.14
6. Indecisiveness (BDI) 2.63 Insomnia, initial (HRSD) 1.28 Loss of Pleasure (BDI) 2.76
7. Phobia (SCAN) 2.39 Dual-action antidepressants (MHF) 0.94 Apparent Sadness (MADRS) 2.65
8. BMI 2.35 Depressed mood (HRSD) 0.87 Pessimism (BDI) 2.17
9. Melancholic symptoms (SCAN) 2.20 Suicidal thoughts (MADRS) 0.62 Concentration difﬁculties (MADRS) 2.13
10. Concentration difﬁculties (MADRS) 1.83 Loss of energy (SCAN) 0.36 Reduced appetite (MADRS) 1.77
Highest accuracy (R2) across models trained in every sample is marked in bold.
R2 ¼ coefﬁcient of determination (proportion of variance explained); beta ¼ standardized regression coefﬁcient (¼ a measure of effect size).
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pants with AUC of 0.72 and a pseudo-R2 over 15% (Supplementary
Table S6 and S7).
4. Discussion
In a comparative study of treatment with two antidepressants, a
combination of demographic and clinical variables predicted
outcome to escitalopram with clinically signiﬁcant accuracy. In
conjunctionwith earlier studies (DeRubeis et al., 2014; Perlis, 2013),
these results suggest that a combination of information from
questionnaires and rating scales can meaningfully contribute to
predict treatment outcome for individual patients.
Prediction models derived from training datasets explained 5%
of variation in symptom improvement overall and10% of variation
in symptom improvement with escitalopram in testing datasets
that were not used in deriving the predictive algorithms. Permu-
tation of outcomes conﬁrmed that the overall and escitalopram-
speciﬁc predictions were signiﬁcantly more accurate than what
could be expected by chance. Escitalopram-speciﬁc outcome pre-
diction was more accurate than generic outcome prediction, and
reached effect sizes that were above a previously established
benchmark for clinical signiﬁcance (Uher et al., 2012d). At least
one-third of the prediction was escitalopram-speciﬁc suggesting
that easy-to-obtain clinical variables can meaningfully contribute
to predict outcome for those treated with this antidepressant drug.
The prediction of outcomes of treatment with nortriptyline was
also numerically more accurate than the overall prediction of
outcome and nearly as strong as for escitalopram, but it could not
be conﬁrmed as statistically signiﬁcant in the permutation test. This
may be due to the fact that individuals allocated to nortriptyline
were more likely to experience adverse effects and to end treat-
ment early. Consequently, nortriptyline-treated participants
contributed on average fewer data points than those treated with
escitalopram. As a result, the measurement of nortriptyline treat-
ment outcome may have been less accurate and the statistical po-
wer to determine robust prediction may have been reduced into he
nortriptyline-treatment arm.
The prediction of remission was strong in both generic anddrug-speciﬁc analyses, with at least comparable predictive power
to previously reported results from an ethnically mixed sample
(Perlis, 2013). Permutation analyses conﬁrmed that the prediction
overall and among escitalopram-treated participants was signiﬁ-
cantly distinct from chance. Combinations of variables predicted
remission with sensitivity and speciﬁcity 0.66, and area under the
curve of 0.72, explaining approximately 15% of variance in who
achieves remission. Such prediction is clinically signiﬁcant (Uher
et al., 2012d). The estimation of variance explained from pseudo-
R2 would suggest that prediction of remission is more accurate than
prediction of symptom reduction. This comparison needs to be
interpreted with caution because the categorical outcome remis-
sion contains less information and because the comparability of
pseudo R2 from logistic analysis with R2 from linear analysis de-
pends on several assumptions. Nonetheless, it is clear that inclusion
of additional symptom predictors improved the prediction of
remission several-fold compared to prediction based on total score
on the depression rating scale, which is known to have a strong
relationship with remission.
Our statistical learning approach allowed to identify and rank
the variables that contributed the most and understand the
mechanism underlying multivariate outcome prediction. The pre-
diction was largely driven by speciﬁc symptom proﬁles. Symptoms
of reduced interest, decreased activity, anxiety, and indecisiveness
contributed to the prediction of all types of outcomes. High scores
on symptom dimension of interest and activity and its component
symptoms contributed to all predictions. More severe ratings on
this dimension were among the strongest predictors of non-
remission to both drugs, in agreement with previously reported
univariate analyses (Uher et al., 2012b). Anxious-somatizing sub-
type of depression strongly predicted poor citalopram treatment
outcome in STAR*D (Fava et al., 2008), but the prediction did not
replicate in GENDEP (Uher et al., 2011). Interestingly, the present
analysis shows that anxious-somatizing depression plays an
important role in the multivariate prediction of remission in
GENDEP, suggesting a complex interplay between anxiety and
other predictors in determining treatment outcomes. Other pre-
dictors were drug-dependent or outcome-dependent. For example,
body mass index and loss of appetite speciﬁcally contributed to the
AC
B
D
Fig. 1. Title: Predictive power of models predicting treatment outcomes from demographic, and clinical variables. Description: “Panel A: Prediction of change in MADRS in the no
randomly allocated sample; Panel B: Prediction of change in MADRS in the Randomly allocated sample; Panel C: Prediction of remission (HRSD) in the no randomly allocated
sample; Panel D: Prediction of remission (HRSD) in the Randomly allocated sample; The y-axes plot the proportion of variance in outcome explained in testing datasets estimated as
R2 for symptom reduction and pseudo R2 for remission. For each outcome the left panel shows results in the whole sample and the right panel shows results in the randomly-
allocated subsample. The red horizontal line marks the previously established benchmark or what is a clinically signiﬁcant prediction. Baseline score on the HRSD scale, which
has a known strong relationship with remission, was excluded from the variable combinations in the lower panels. For comparison, the ﬁrst (bright yellow) bar marks the prediction
of remission from baseline total score on the HRSD scale. The last (green) bar marks the cross-drug prediction of remission, i.e. the proportion of variance in outcome explained in
the escitalopram-treated sample by the best model in predicting outcome in the nortriptyline-treated sample and the proportion of variance in outcome explained in the
nortriptyline-treated sample by the best model in predicting outcome in the escitalopram-treated sample.”. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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2009b). The prediction proﬁles conﬁrm ﬁndings from previous
univariate analyses and extend these to demonstrate their joint
predictive power to optimize prediction at the level of individual.
Prediction of trial completion was substantially less accurate
than prediction of remission. Prediction of treatment resistance
was intermediate. This may reﬂect reduced power in predicting less
common outcomes, heterogeneity in determinants of trial discon-
tinuation or uncertainty in the deﬁnition of TRD, which partly de-
pends on recollection of past treatment trials. Prediction of these
outcomes may beneﬁt from inclusion of additional variables.
We included most previously-reported predictors of treatment
outcome in the predictive models, including demographic and
physical variables (age, body mass index, social status), concurrent
anxiety, symptom dimension of interest-activity, suicidal thoughts
and behaviours, treatment history and life events (Keers et al.,
2010; Uher et al., 2011; 2009a; 2009b; 2012b; 2012c). Other
potentially predictive variables were not included because they
were invariant in this relatively homogeneous sample (e.g.
ethnicity, some comorbid disorders, family history of bipolar dis-
order) or the data were not available (e.g. personality disorders
were not assessed in GENDEP). While this degree of inclusiveness
provided a scope of predictors for multivariate analyses, the se-
lection can by no means be considered exhaustive. At present, itremains unclear why some predictors' contribution depends on
outcome (e.g. loss of appetite contributes to the prediction of
remission but not to the prediction of symptom improvement).
Other predictors, such as interest-activity symptom dimension,
contribute consistently to predicting all types of outcomes and are
likely to be included in further reﬁnements of models predictive of
depression treatment outcomes.
Our results should be interpreted with regard to the limitations
of carrying a complex analysis in a ﬁnite dataset with imperfect
measurement. We used a 10-fold cross-validation to identify pre-
dictors of outcome. Although this is a rigorous approach, in some
cases cross-validation can lead to misestimation of the effect sizes
(Kim, 2009). We have conﬁrmed the speciﬁcity and robustness of
our results in various ways. We averaged cross-validation estima-
tors across 100 repetitions, performed cross-drug analyses and
used permutation testing to provide a signiﬁcance value for the
prediction. Although testing the models in an independent set of
unseen cases would be the most reliable way of estimating the
generalizability of the predictive capacity of our predictors, the
number of clinical variables that overlapped between GENDEP and
other studies was much smaller than what we used (Investigators
et al., 2013; Perlis, 2013). These studies also explored different
drugs than GENDEP or a mixture of drugs, precluding the validation
of drug-speciﬁc predictors. Alternatively, the statistical signiﬁcance
A.
B.
Fig. 2. Title: Null distribution for R2 and pseudo-R2 values for models predicting treatment outcome. Description: “Distribution of 10-fold-cross-validation R2 and pseudo-R2 values
computed in 1000 samples with the outcomes randomly permuted. X-axes plot the R2 and pseudo-R2 range of values over 1000 samples with permuted outcome. Y-axes plot the
histogram for the observed frequencies for R2 and pseudo-R2 over the 1000 samples. The distribution is considered as the null distribution for R2 and pseudo-R2, and used to derive
the p values for the R2 and pseudo-R2 estimations obtained using real outcome, marked with a red square in the plot. Panel A: Null distribution for R2 for models predicting
percentage change in MADRS in the whole sample, and in the subgroups of patients randomly-allocated to nortriptyline or escitalopram arms. Panel B: Null distribution for pseudo-
R2 for models predicting remission (HRSD) in the whole sample, and in the subgroups of patients randomly-allocated to nortriptyline or escitalopram arms. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 3
Predicting remission.
All Both antidepressants Escitalopram Nortriptyline
Sample size n ¼ 793 n ¼ 465 n ¼ 328
pseudo R2 AUC pseudo R2 AUC pseudo R2 AUC
Baseline HRSDa 0.048 0.69 0.036 0.65 0.029 0.70
Combination I 0.006 0.61 0.008 0.60 0.019 0.63
Combination II 0.157 0.72 0.160 0.72 0.150 0.70
Combination III 0.164 0.71 0.169 0.72 0.208 0.70
Combination IV 0.149 0.72 0.183 0.72 0.165 0.70
Best model: IV IV II
Cross-drug prediction pseudo R2 AUC pseudo R2 AUC
Escitalopram e e 0.022 0.50
Nortriptyline 0.013 0.53 e e
No. predictors retained: 41 46 52
Strongest effect size: Predictor OR Predictor OR Predictor OR
1. Appetite (Dimension) 0.82 Appetite (Dimension) 0.78 BMI 0.87
2. Phobia (SCAN) 0.85 Benzodiazepine (yes) 0.83 Pessimism (Dimension) 0.90
3. Interest-activity (Dimension) 0.85 Fatiguability (SCAN) 0.83 Anxious-somatizing depr. (SCAN) 0.90
4. BMI 0.88 Anhedonia (SCAN) 1.15 Phobia (SCAN) 0.91
5. Age 0.88 Phobia (SCAN) 0.86 Interest-activity (Dimension) 0.91
6. Anxious-somatizing depr. (SCAN) 0.89 Age 0.87 Melancholic depression (SCAN) 1.09
7. Benzodiazepine (MHF) 0.91 Interest-activity (Dimension) 0.88 Appetite (Dimension) 0.91
8. Pathological guilt (SCAN) 1.09 Preoccupation with death (SCAN) 1.11 Loss of libido (SCAN) 0.92
9. Cognitive (Factor) 0.91 Smoker (yes) 0.89 Age 0.92
10. Hopelessness (SCAN) 0.92 Pathological guilt (SCAN) 1.10 Hopelessness (SCAN) 0.93
Highest accuracy (AUC) across models trained in every sample is marked in bold.
Pseudo R2 ¼ log-likelihood pseudo R2 (estimated proportion of variance explained in logistic regression); AUC ¼ area under the curve; OR ¼ odds ratio.
a Baseline HRSD variables were excluded from all combinations.
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Table 4
Predicting remission among randomly allocated participants.
Randomly allocated Both antidepressants Escitalopra Nortriptyline
Sample size n ¼ 450 n ¼ 232 n ¼ 218
pseudo R2 AUC pseudo R2 AUC pseudo R2 AUC
Baseline HRSDa 0$059 0$69 0$04 0$70 0$028 0$65
Combination I 0$018 0$63 0$011 0$63 0$028 0$65
Combination II 0.224 0.74 0$246 0$72 0.187 0.72
Combination III 0$203 0$73 0$141 0$72 0$196 0$70
Combination IV 0$217 0$74 0.458 0.75 0$204 0$70
Best model: II IV II
Cross-drug prediction pseudo R2 AUC pseudo R2 AUC
Escitalopram e e 0$029 0$57
Nortriptyline 0$006 0$50 e e
No. predictors retained: 41 46 52
Strongest effect size: Predictor OR Predictor OR Predictor OR
1. Interest-activity (Dimension) 0$77 Interest-activity (Dimension) 0$75 BMI 0$84
2. Anxious-somatizing depr. (SCAN) 0$78 Phobia (SCAN) 0$76 Anxious-somatizing depr. (SCAN) 0$88
3. Phobia (SCAN) 0$79 Appetite (Dimension) 0$77 Appetite (Dimension) 0$90
4. Appetite (Dimension) 0$80 Suicidality (SCAN) 1$22 Hopelessness (SCAN) 0$91
5. Age 0$82 Smoker (yes) 0$81 Interest-activity (Dimension) 0$91
6. BMI 0$82 Anxious-somatizing depr. (SCAN) 0$81 Irritability (SCAN) 1$09
7. Suicidality (SCAN) 1$18 Age 0$83 Restlessness (SCAN) 0$91
8. Melancholic depression (SCAN) 1$16 Neurovegetative (Factor) 0$86 Age 0$91
9. Loss of appetite (SCAN) 1$15 Anxiety, somatic (SCAN) 0$86 Pessimism (Dimension) 0$91
10. Smoker (yes) 0$87 Cognitive (Factor) 0$88 Loss of libido (SCAN) 0$91
Highest accuracy (AUC) across models trained in every sample is marked in bold.
Pseudo R2 ¼ log-likelihood pseudo R2 (estimated proportion of variance explained in logistic regression); AUC ¼ area under the curve; OR ¼ odds ratio.
a Baseline HRSD variables were excluded from all combinations.
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our results, suggesting a signiﬁcant prediction for our clinical
predictors.
In summary, the present study suggests that easily obtained
demographic and clinical variables can predict response to escita-
lopram with clinically meaningful accuracy. The obtained results
might have the potential to individualized prescription of this an-
tidepressant. Combination with biochemical, genetic, electrophys-
iological and neuroimaging biomarkers may further increase the
prediction accuracy. The present study provides a basis that can be
used to test the added beneﬁts of more intensive measurements.
The R code of the model to predict escitalopram outcome is
available upon request from raquel.iniesta@kcl.ac.uk.Acknowledgment
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